Effects of gold and PCL- or PLLA-coated silica nanoparticles on brain endothelial cells and the blood–brain barrier by Bittner, Aniela et al.
941
Effects of gold and PCL- or PLLA-coated silica nanoparticles
on brain endothelial cells and the blood–brain barrier
Aniela Bittner1, Angélique D. Ducray1, Hans Rudolf Widmer2, Michael H. Stoffel3
and Meike Mevissen*1
Full Research Paper Open Access
Address:
1Division of Veterinary Pharmacology and Toxicology, Vetsuisse
Faculty, University of Bern, Länggassstrasse 124, 3012 Bern,
Switzerland, 2Department of Neurosurgery, Research Unit, Inselspital,
University of Bern, Freiburgstrasse 8, 3010 Bern, Switzerland and
3Division of Veterinary Anatomy, Vetsuisse Faculty, University of
Bern, Länggassstrasse 120, 3012 Bern, Switzerland
Email:
Meike Mevissen* - meike.mevissen@vetsuisse.unibe.ch
* Corresponding author
Keywords:
blood–brain barrier; laser tissue soldering; nanomedicine;
nanoparticle uptake; rBCEC4 cells
Beilstein J. Nanotechnol. 2019, 10, 941–954.
doi:10.3762/bjnano.10.95
Received: 17 December 2018
Accepted: 04 April 2019
Published: 25 April 2019
Associate Editor: J. Lahann
© 2019 Bittner et al.; licensee Beilstein-Institut.
License and terms: see end of document.
Abstract
Nanomedicine is a constantly expanding field, facilitating and improving diagnosis and treatment of diseases. As nanomaterials are
foreign objects, careful evaluation of their toxicological and functional aspects prior to medical application is imperative. In this
study, we aimed to determine the effects of gold and polymer-coated silica nanoparticles used in laser tissue soldering on brain en-
dothelial cells and the blood–brain barrier using rat brain capillary endothelial cells (rBCEC4). All types of nanoparticles were
taken up time-dependently by the rBCEC4 cells, albeit to a different extent, causing a time- and concentration-dependent decrease
in cell viability. Nanoparticle exposure did not change cell proliferation, differentiation, nor did it induce inflammation. rBCEC4
cells showed blood–brain barrier characteristics including tight junctions. None of the nanoparticles altered the expression of tight
junctions or impaired the blood–brain barrier permeability. The findings suggest that effects of these nanoparticles on the meta-
bolic state of cells have to be further characterized before use for medical purposes.
Introduction
Nanotechnology is commonly used in various fields, such as
agriculture and pharmaceutical industry, and has gained further
importance over the past few decades [1]. This technology also
offers promising possibilities for medical applications such as
tumor diagnostics and therapy, as drug carriers or in biodegrad-
able implants, e.g., in laser tissue soldering (LTS) [2].
LTS provides a promising alternative treatment method for
injuries of hollow organs, e.g., vessels, offering faster proce-
dure time, immediate watertightness, faster wound healing and
reduced recovery time compared to classical microsuturing
[3-5]. This technique makes use of a degradable polymer scaf-
fold containing albumin and the chromophore indocyanine
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green (ICG). The latter enables the transduction of laser light
into heat leading to denaturation of the albumin and, subse-
quently, tissue fusion [6]. As ICG is unstable in aqueous solu-
tions and prone to fast photo-bleaching, the use of a stabilizing
system, such as encapsulation in nanoparticles (NPs), increases
precision and success of the procedure. Alternatively, gold NPs
(Au-NPs) allow for localized and precise application of LTS
[7,8].
Nanomaterials are foreign materials and, hence, might elicit
adverse effects when they come in contact with bodily tissue,
vessels and specialized structures such as the blood–brain
barrier (BBB). To be able to safely employ LTS in nanomedi-
cine, such unwanted effects need to be studied.
Previously, we investigated effects of silica (Si-), namely silica-
ICG/poly(ε-caprolactone) (PCL) and silica-ICG/poly(ε-capro-
lactone-poly(L-lactide) (PLLA), and Au-NPs used in LTS on
cells of the brain, namely microglial and neuron-like cells.
Si-NPs were further characterized regarding their interactions
with cells by using organotypic hippocampal tissue slices and
primary cultures. All types of NPs were found in microglial
cells and neuron-like cells in membrane-surrounded vesicles
and the cytoplasm. Studies in organotypic brain slices revealed
that NPs were only taken up by microglial cells but not by
astrocytes or neurons [9]. NPs were taken up in a time- and con-
centration-dependent manner and were found in the endo-
plasmic reticulum and lysosomes in microglia [10]. None of the
NPs investigated resulted in cytotoxicity, decreased cell
viability, apoptosis, autophagy or inflammation. However,
exposure to NPs led to oxidative stress via depletion of cellular
glutathione and to a downregulation of neuronal differentiation
markers in neurons [11]. Kamikobu et al. reported that the
effect of Si-NPs on cell viability of embryonic kidney cells and
primary hippocampal cultures depended on concentration, size
and surface charge of the particles. Notably, neuronal cells were
shown to be more sensitive to NP exposure compared to embry-
onic kidney cells. Si-NPs induced time- and concentration-de-
pendent neuronal cell death by production of reactive oxygen
species and reduction of glutathione levels [12]. Similarly,
Si-NPs led to morphological changes, concentration-dependent
membrane damage, decreased cell viability, increased apopto-
sis, oxidative stress and an increase in inflammatory cytokines
in dopaminergic neuron-like cells. In vivo intranasal administra-
tion of these NPs corroborated these findings and showed local-
ization of Si-NPs mainly in the striatum and hippocampus [13].
As LTS finds its application in vessels of the brain, the effects
of various NPs on cells of the vasculature and the BBB need to
be determined. The BBB is made of specialized endothelial
cells (ECs), astrocytes and pericytes, forming a tight barrier,
thus restricting access to the brain [14,15]. Disruption of this
barrier allows potentially harmful molecules to enter the brain
and cause or worsen diseases of the central nervous system [16]
that NPs might contribute to [17].
Coated or uncoated mesoporous Si-NPs of different size and
zeta potential did not elicit considerable cytotoxicity in MDCK
II kidney epithelial cells or RBE4 rat brain ECs but were taken
up by both cell types. However, uptake was found to be more
prominent in RBE4 cells compared to MDCK II cells [18].
After exposure of rat primary cultured brain microvessel ECs
(rBMECs) to Au-NPs, smaller NPs were demonstrated to be
taken up to a higher extent compared to larger NPs. Overall,
only the smallest Au-NPs showed an effect on cell viability.
Regardless of size, none of the NPs induced inflammation or
cell morphology changes [19]. This could also be shown for pri-
mary cultured porcine brain microvessel ECs (pBMECs)
exposed to Au-NPs [20]. Si-NPs elicited concentration- and
time-dependent cytotoxicity in HUVECs. Furthermore, Si-NPs
were shown to induce oxidative stress and inflammation medi-
ated by mitogen-activated protein kinase (MAPK) and nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB)
[21] pathways that are related to cell proliferation and differen-
tiation but also to inflammation and apoptosis via connection to
the NF-κB pathway [22].
Size- and dose-dependent cytotoxicity and disruption of the
BBB after exposure to SiO2 particles were shown in a human
model and confirmed in vivo [23]. Integrity and function of the
BBB of primary porcine brain microvascular ECs (PBECs) in
co-culture with SH-SY5Y cells were not affected by exposure
to PEGylated Au-NPs [24]. Similar results were reported by
Trickler et al. using Au-NPs in both a rat and a porcine model
of the BBB. Smaller Au-NPs, however, increased the BBB-
permeability in the rBMEC monolayer but not the pBMEC
monolayer [19].
In the context of LTS, ECs will be in direct contact with NPs
being released from the degrading scaffold [25]. The same
holds true for intravascular applications of NPs in general.
Hence, in this study, brain ECs, rBCEC4, were used to exam-
ine possible effects of two types of Si-NPs as well as Au-NPs
on cell viability, induction of inflammation and uptake and
intracellular localization of NPs.
Results
NP effects on rBCEC4 cell viability
rBCEC4 cells were exposed to five different NP concentrations
for each of the three NP types used, namely PCL-, PLLA- and
Au-NP, for 2 and 24 h (Figure 1). Regardless of the concentra-
tion, neither PCL- nor PLLA-NPs affected cell viability after
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Figure 1: Concentration-dependent effects of PCL- (A), PLLA- (B) and
Au- (C) NPs on rBCEC4 cell viability. A time- and concentration-de-
pendent effects was detected after exposure to all three types of NPs.
Concentrations of PCL- or PLLA-NPs were [2.49 × 10−7 µg/mL] to
[24.9 µg/mL] and of Au-NPs [1.6 × 10−6 µg/mL] to [160.3 µg/mL] with
100-fold increases in between. Error bars represent SEM. Control:
non-exposed cells. Significant differences between NP-exposed and
non-exposed control are labeled with circles (°) for 2 h of NP exposure
and asterisks (*) for 24 h of NP exposure, respectively (°/* = p ≤ 0.05;
** = p ≤ 0.01; *** = p ≤ 0.001; **** = p ≤ 0.0001).
2 h of exposure even though a high percentage of cells (57% for
PCL-NPs and 46% for PLLA-NPs) had taken up NPs. In
contrast, Au-NP concentrations of [160.3 µg/mL] and
[0.16 ng/mL] caused a significant decrease in cell viability of
10%. After 24 h of exposure, a significant effect on cell
viability could be detected at the highest NP concentration re-
sulting in a decrease of 50%, 40% and 30% for PCL-, PLLA-
and Au-NPs, respectively. All NP types and concentrations
resulted in a decrease in cell viability of less than 20% with the
exception of exposure to [0.25 µg/mL] PCL-NP for 24 h.
Overall, PCL-NPs exhibit the most pronounced effect on the
viability of rBCEC4 cells as shown in Figure 1.
NP uptake in rBCEC4 cells
Uptake of PLLA-, PCL- and Au-NPs was first investigated with
TEM (Figure 2), revealing differences between these three NP
types. Both PLLA- and PCL-NPs were taken up to a high extent
after 2 and 24 h of exposure, respectively. They tended to form
clusters and were detected freely in the cytosol or in membrane-
bound vesicles (Figure 2A,D and Figure 2B,E). On the other
hand, Au-NPs could not be found inside rBCEC4 cells after 2 h
of exposure. Prolonging exposure to 24 h resulted in the uptake
of few, single Au-NPs co-localizing with heterolysosomes as
illustrated in Figure 2C,F.
As both types of Si-NPs were fluorescent, NP uptake was
further examined using fluorescent markers for the cytoskeleton
(data not shown) and various cell organelles (Figure 3A–D).
PCL- and PLLA-NPs were observed inside the cells but not in
co-localization with mitochondria, the Golgi apparatus, endo-
plasmic reticulum or lysosomes. Both NP types were found pre-
dominantly close to the nucleus. PCL- and PLLA-NP uptake
was also assessed quantitatively with high-content analysis
using a fully automated inverted epifluorescence microscope
(Figure 3E). As Au-NPs were only taken up to a very low
extent, quantification was not carried out for these. PCL- and
PLLA-NP uptake was measured after 0.5, 2 and 24 h of expo-
sure to a concentration of [24.9 µg/mL]. A time-dependent sig-
nificant increase in NP uptake was obtained in rBCEC4 cells.
Both PCL- and PLLA-NPs were taken up to a very similar
extent. After 24 h of NP exposure, 87% and 84% of cells had
taken up PCL- and PLLA-NPs, respectively (Figure 3E).
Signaling pathways involved in survival,
proliferation and inflammation in rBCEC4
cells
Possible changes in protein expression representing inhibition
or activation of several crucial proteins of different signaling
pathways involved in regulatory processes including cell
survival and proliferation were investigated with western blot-
ting. The active, phosphorylated (P-) form of the proteins of
interest was compared to their inactive, non-phosphorylated
form.
Protein kinase B (Akt) could be detected in its inactive and
active form but neither exposure to Si- nor to Au-NPs caused
significant changes in its expression. However, a trend to an
increase in P-Akt was seen after Au-NP exposure (Figure 4A).
MAPK and P-MAPK were both expressed in unexposed and
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Figure 2: Uptake of PLLA-NPs (A, D) after 2 h of exposure and uptake of PCL-NPs (B, E) and Au-NPs (C, F) into rBCEC4 cells after 24 h of expo-
sure; cell overview (A, B, C) and higher magnification (D, E, F); analyzed by TEM. PLLA- and PCL-NPs were found in clusters inside the cells
(arrows) (A, B; scale bar: 5 µm) and were present freely in the cytoplasm (arrows) or in membrane-bound vesicles (arrow head) (D, E; scale bar:
1 µm). Single Au-NPs were taken up by the cells (arrows) (C; scale bar: 2 µm) and co-localized with heterolysosomes (arrows) (F; scale bar: 1 µm).
Nuc = nucleus, HL = heterolysosomes, Rib = free ribosomes; Mi = mitochondria; Go = Golgi apparatus; ER = endoplasmic reticulum. Concentrations
were [24.9 µg/mL] PLLA- or PCL-NPs and [160.3 µg/mL] Au-NPs.
exposed rBCEC4 cells. MAPK was present at similar levels
under all conditions for all three NP types, whereas differences
were visible in P-MAPK expression after NP exposure. PCL-
and PLLA-NP exposure caused a significant decrease in phos-
phorylation of MAPK when compared to unexposed control
cells. This decrease was more prominent in PLLA-NP-exposed
cells compared to PCL-NP-exposed cells. Au-NPs on the other
hand, resulted in an increase in P-MAPK that was not statisti-
cally significant, as shown in Figure 4B. Neither Si- nor
Au-NPs led to differences in activation or expression of NF-κB.
Both forms could be detected for this protein (Figure 4C).
Expression of tight-junction proteins in
rBCEC4 cells
Immunofluorescence staining and TEM were used to demon-
strate the expression of important BBB-characteristics, namely
tight junction (TJ) formation, in rBCEC4 cells. Both, the TJ-as-
sociated protein zonula occludens-1 (ZO-1) and the TJ protein
occludin, resulted in positive staining (Figure 5A,B). TEM
pictures corroborated the formation of TJs between single
rBCEC4 cells in a cell monolayer (Figure 5C).
A possible effect of NP exposure on TJ formation and estab-
lished TJs was investigated using immunofluorescence staining
for ZO-1 (Figure 5D–G). rBCEC4 cells were exposed to PLLA-
NPs at a concentration of [24.9 µg/mL] at various time points
during and after monolayer and barrier formation. No differ-
ences in signal intensity or continuity of ZO-1 between control
cells and any of the conditions of PLLA exposure were
detected. PCL-NP exposure did not elicit changes in immuno-
fluorescence staining of ZO-1 either (data not shown). No varia-
tions in protein levels of ZO-1 and TJ protein claudin 3 were
observed after exposure to PCL-, PLLA- or Au-NPs compared
to non-exposed controls (Figure 6A,B).
β-Catenin, the key player in the canonical Wnt signaling path-
way, has been demonstrated to regulate and coordinate cell–cell
adhesion by formation and stabilization of adherens and tight
junctions [26]. The active, unphosphorylated form was
expressed under all experimental conditions. The phosphorylat-
ed form could not be detected. NP exposure did not induce
changes in the level of β-catenin protein expression between
exposed and non-exposed cells after incubation with rBCEC4
cells for 24 hours (Figure 6C).
Effect of NPs on blood–brain barrier
permeability
rBCEC4 cells were grown on filter insert membranes to allow
for the investigation of NP effects on BBB permeability. The
transport of two tracers across the cell monolayer and
transendothelial electrical resistance (TEER) were measured.
TEER measurements showed a statistically significant increase
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Figure 3: Representative microscopic images of rBCEC4 cells stained for various cell organelles (green) exposed to PCL- (A, B) or PLLA-NPs (C, D)
for 24 h. No NPs (red) were found in mitochondria (ATPB-positive organelles) (A), Golgi apparatus (giantin-positive organelles) (B), lysosomes
(LAMP1-positive organelles) (C) or in the ER (calreticulin-positive organelles) (D). Cell nuclei were counterstained with Hoechst (blue). Scale bars
10 µm. Uptake of PCL- and PLLA-NPs into rBCEC4 cells after 0.5, 2 or 24 h of NP exposure was quantified using high-content analysis (E). Both
PCL- and PLLA-NPs showed a similar and time-dependent uptake pattern. Concentrations of PCL- or PLLA-NPs were [24.9 µg/mL]. Error bars repre-
sent SEM. Significant differences between exposure times are labeled with asterisks (*) (* = p ≤ 0.0001).
over time (Figure 7A). After NP exposure ([24.9 µg/mL] PCL-
NPs or [160.3 µg/mL] Au-NPs for 24 h) and DMSO stimula-
tion on DIV2, no changes were observed in PCL-NP-treated
cell monolayers. However, as expected, DMSO stimulation
resulted in a strong decrease of TEER on DIV3 as illustrated in
Figure 7A. Only empty filters (no cell monolayer) and DMSO-
treated rBCEC4 cell layers showed significantly increased
permeability compared to filters with cells, untreated or
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Figure 4: Effects of PCL-, PLLA- and Au-NP exposure on various signaling pathways. Expression of phosphorylated and unphosphorylated forms of
crucial proteins of the Akt, the MAPK and the NF-κB pathway after 24 h of exposure to all three NP types was quantified and the ratios (phosphorylat-
ed/unphosphorylated) were calculated. PCL-, PLLA- and Au-NPs did not affect expression or activation of Akt or NF-κB (A, C). PCL- and PLLA-NPs
led to decreased levels of P-MAPK, whereas Au-NPs caused an increase (B). Representative western blot images are depicted on the left; quantifica-
tion is shown on the right. Co: control. Concentrations were [24.9 µg/mL] for PCL- and PLLA-NPs and [160.3 µg/mL] for Au-NPs. Error bars represent
SEM. Significant differences between NP-exposed and non-exposed controls are labeled with asterisks (*) (* = p ≤ 0.05; ** = p ≤ 0.01;
*** = p ≤ 0.001).
NP-exposed. The permeability of NP-treated filters did not
differ from that of untreated control filters as depicted in
Figure 7B and Figure 7C. Furthermore, no difference between
PCL- and Au-NP-exposed cell monolayers was detected.
Overall, cell monolayers are less permeable to 70 kDa FITC
dextran (Figure 7C) than to 4.4 kDa TRITC dextran
(Figure 7B).
Discussion
A concentration- and time-dependent effect of exposure to all
three NP types on rBCEC4 cell viability was detected with the
effect being most prominent after 24 h of PCL exposure. At
similar NP concentrations, Au-NPs displayed a lower cytotoxic-
ity for rBCEC4 cells compared to PCL- or PLLA-NPs. Con-
trary to this, coated or uncoated mesoporous Si-NPs of differ-
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Figure 5: Representative microscopic images of rBCEC4 cells stained for TJs. Staining (green) shows expression of ZO-1 (A, D-G) and occludin (B)
in rBCEC4 cells. TEM further confirmed existence of TJs in these cells (C). PLLA-NPs were used to investigate possible effects of NP exposure on
rBCEC4 cells: control (D), PLLA-NPs were added shortly after seeding the cells (E), about 24 h before cells reached full confluence (F) and after
monolayer formation (G). No difference between control and any of the three conditions of NP exposure could be detected. PLLA-NPs are shown in
red. Cell nuclei were counterstained with Hoechst (blue). Concentration of PLLA-NPs was [24.9 µg/mL]. Scale bars: 10 µm (A, B, D–G). Scale bar
1 µm (C).
ent shape, size (50 to 240 nm) and zeta potential (negative to
neutral) did not elicit cytotoxicity in MDCK II kidney epithe-
lial cells and RBE4 ECs at concentrations of up to [50 µg/mL]
[18]. As the highest concentration for polymer-coated Si-NPs
used in our study was half ([24.9 µg/mL]), the different effects
may be due to differences in NP characteristics. PEG-b-PCL-
NPs were highly biocompatible and did not cause significant
cell viability reductions when added to hCMEC/D3 cells at con-
centrations of [0.01–1 mg/mL] [27]. PCL-NPs resulted in dif-
ferent cytotoxicity in human retinal vascular ECs, exhibiting
stronger effects in the latter at concentrations of [25 µg/mL] to
[200 µg/mL] with up to 50% reduction in cell viability [28], in-
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Figure 6: Effects of PCL-, PLLA- and Au-NPs on expression and regulation of TJs in rBCEC4 cells. Expression levels of ZO-1 (A), claudin 3 (B) and
β-catenin (C) were evaluated and quantified. None of the NPs exhibited an effect on the expression levels of these proteins. Representative western
blot images are depicted on the left, corresponding quantifications are shown on the right. Co: control. Concentrations were [24.9 µg/mL] for PCL- and
PLLA-NPs and [160.3 µg/mL] for Au-NPs. Error bars represent SEM.
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Figure 7: Effects of PCL- or Au-NP exposure on TEER (Ω·cm2) and
permeability of an rBCEC4 monolayer. Permeability is indicated by
Papp (cm/s). An increase in TEER was observed over the 3 days in cul-
ture (DIV: days in vitro). DMSO resulted in a significant decrease of
TEER whereas NP exposure did not. The dashed line signifies the
start of NP exposure and DMSO stimulation (A). None of the NPs ex-
amined led to a change in permeability, regardless of the tracer used –
4.4 kDa TRITC dextran (B) or 70 kDa FITC dextran (C). Concentra-
tions were [24.9 µg/mL] for PCL-NPs, [160.3 µg/mL] for Au-NPs and
10% DMSO. Error bars represent SEM. Significant differences to
empty filters and DMSO are labeled with asterisks (*) or circles (°), re-
spectively (B, C). (°/* = p ≤ 0.01; ** = p ≤ 0.0001).
dicating that different cell types react differently to similar NPs.
In line with our findings, 20 nm PEGylated Au-NPs did affect
the proliferation of HUVECs up to concentrations of
[100 µg/mL], a lower Au-NP concentration than the one used in
our study ([160.3 µg/mL]) [24]. Unremarkable changes in cell
viability were detected after exposure of rBMECs to
[0.8–50 µg/mL] of various sizes of Au-NPs [19] but again, the
NP concentrations used in the present study were three times
higher. Besides the NP concentration, physicochemical proper-
ties, especially surface characteristics were demonstrated to be
important for the interactions with cells [29-31]. Hence, varia-
tions in surface characteristics, composition and size of the NPs
and the various cell types used are likely to account for differ-
ences between the studies. This is corroborated by comparisons
of the effects of different types of NPs on the cell viability of
different cell types [28,32].
All three NP types were taken up by rBCEC4 cells, but with
variations in extent and duration demonstrated by higher and
faster uptake of PCL- and PLLA-NPs than of Au-NPs. High-
content analysis resulted in almost 90% of rBCEC4 cells with
internalized PCL- or PLLA-NPs after 24 h of exposure. This is
rather surprising and reminds of the extent of uptake in
microglial cells where NPs were also found in lysosomes [10].
Previously published data showed that neurons take up NPs
when they are kept in monoculture, whereas this was not the
case in organotypic slice cultures, where NPs were predomi-
nantly found in microglia [9]. Therefore, the lack of other cell
types in the rBCEC4 monoculture might explain the high
amount of cells containing NPs. Similar to our findings, meso-
porous Si-NPs were taken up by both epithelial, MDCK II, and
endothelial cells, RBE4. Uptake was shown to be enhanced by
copolymer coating and was found more prominent in RBE4
cells compared to MDCK II cells [18]. In contrast to our find-
ings, Trickler et al. found a size-dependent rapid accumulation
of Au-NPs in rBMECs within 30 min [19]. In agreement with
the co-localization of Au-NPs with heterolysosomes found in
our study, Au-NPs of the same size (80 nm) were shown to be
taken up by HUVECs, localizing in endosomes and lysosomes
[33]. Besides physicochemical properties, the formation of NP
clusters before entry into the cell may modulate the cellular
uptake [9,34].
NPs might not only cause cytotoxicity but also hinder prolifera-
tion, differentiation or lead to inflammation via activation or
inhibition of various pathways including phosphatidylinositol-
3-kinase/Akt (PI3K-Akt) [35], MAPK and NF-κB [22]. Hence,
the expression of different key proteins after exposure to PCL-,
PLLA- and Au-NPs was evaluated. P-MAPK-expression was
significantly altered after exposure to PCL-NPs and PLLA-NPs
but not to Au-NPs. A decrease in phosphorylation was detected
in cells that had been exposed to either PCL- or PLLA-NPs
with PLLA-NPs eliciting a slightly more prominent effect.
Compared to this, TiO2-NPs caused increases in phosphoryla-
tion of Akt and all three MAPKs followed by activation of
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NF-κB [36]. Guo et al. demonstrated that Si-NP exposure in-
duced inflammation in the human endothelial cell line HUVEC.
The effects were mediated by the induction of phosphorylation
of proteins involved in oxidative signaling and inflammation,
namely two key MAPKs – JNK and p38 MAPK – and NF-κB
[21]. This is in contrast to our study, in which none of the NPs
investigated had a significant effect on the expression levels of
Akt or NF-κB or their respective phosphorylated forms indicat-
ing that the NPs do not modulate cell proliferation and inflam-
mation. The fact that the MTT assay measures the metabolic ac-
tivity of a cell might explain the lack of alterations in markers
of proliferation pathways [37,38].
For LTS in the brain, ECs representing BBB characteristics in-
cluding TJs are important to allow for the investigation of the
effects of NPs on BBB integrity. We could show that rBCEC4
cells express TJs and TJ-related proteins, namely occludin,
claudin 3 and ZO-1. None of the NPs investigated impaired
expression, integrity or functionality of TJs. In accordance with
our findings, PEGylated Au-NPs did not alter TJ expression,
TEER or Papp of a co-culture model consisting of PBECs and
SH-SY5Y [24]. Copper and Ag-NPs on the other hand led to an
increase in permeability of the PBMEC monolayer [19,20].
Liu et al. showed a size-dependent effect of SiO2 particles on
the expression of occludin and ZO-1 and BBB permeability
with particles in the nanometer range causing a decrease in TJ
protein expression and an increase in permeability, whereas
microparticles did not affect either [23]. Surface-modified
poly(lactide-co-glycolide) NPs decreased TEER and increased
permeability in a HBMEC–human astrocyte co-culture model
[39]. Compared to a BBB model using hCMEC/D3 cells, TEER
and Papp values in our model, albeit being slightly lower and
higher, respectively, were comparable [40]. However, models
using primary ECs resulted in higher TEER and lower overall
permeability [19,23,24]. Overall, various BBB models have
been established and improved over the past few decades, ex-
hibiting varying degrees of in vivo BBB characteristics and thus
variable suitability for studying certain aspects of the BBB [41-
43]. This underlines the importance of carefully choosing the
correct model for the intended purpose of the study.
Conclusion
The data obtained for the assessment of effects of PCL-, PLLA-
and Au-NPs used in LTS in the brain, except for reduced cell
viability, do not indicate an impairment of the BBB and func-
tional integrity in rBCEC4 cells under the given experimental
conditions. The influence of NPs on the metabolic state of the
cells needs to be investigated. Due to the simplistic nature of the
model used, the results need to be assessed with BBB models,
namely co-culture or 3D models that mimic the in vivo situa-
tion more closely.
Experimental
Cell culture
The immortalized rat brain capillary endothelial cell line
rBCEC4 was characterized and kindly provided by Dr. Ingolf E.
Blasig (Leibniz-Forschungsinstitut für Molekulare Phar-
makologie, Berlin, Germany) [44]. Cells were grown on
0.1% gelatin (bovine origin; Sigma, Switzerland) in Dulbecco’s
Modified Eagle Medium (DMEM; Life Technologies, UK)
substituted with 10% heat-inactivated fetal bovine serum (FBS;
Life Technologies, UK) and penicillin (100 units/mL) – strepto-
mycin (100 µg/mL) (Life Technologies, UK) at 37 °C and
5% CO2.
Nanoparticles
Silica-ICG/poly(ε-caprolactone) (PCL) and silica-ICG/poly(ε-
caprolactone-poly(L-lactide) (PLLA) NPs were constructed and
provided by Prof. Dr. Uwe Pieles, Department of Chemistry and
Bioanalytics, Academy of Life Science, Switzerland. Both types
of NPs consisted of a silica-core doped with rhodamine to
enable visualization via fluorescence microscopy, followed by a
layer of PCL/ICG and a surface coating with either PCL or
PLLA. Characterization of these particle types showed a size of
90 nm for PCL-NPs and 95 nm for PLLA-NPs. The zeta poten-
tial was −25.4 mV and −15.9 mV for PCL- and PLLA-NPs, re-
spectively [45]. To achieve homogenous distribution of Si-NPs
in solution, both PCL- and PLLA-stock solutions were soni-
cated prior to incubation with cells. Sonication was carried out
for 4 min at 30% amplitude on ice followed by a 5 min pause,
and repeated three times. PCL- and PLLA-NP-stock solutions
were then diluted 1:10 in cell culture medium, resulting in con-
centrations of 2.9 × 1010 PCL-NPs in 1 mL culture medium and
2.6 × 1010 PLLA-NPs in 1 mL culture medium. These concen-
trations correspond to [24.9 µg/mL].
Au-NPs exhibiting size and surface characteristics similar to
those of the Si-NPs used were purchased from Nanopartz
(Nanopartz Inc., USA). They were 80 nm in diameter, with a
zeta potential of −35 mV. Au-NPs were sonicated for 5 min in a
sonication bath and vortexed for 2 min prior to dilution in cell
culture medium. rBCEC4 cells were exposed to a final concen-
tration of 3.55 × 1010 Au-NPs per 1 mL culture medium
([160.3 µg/mL]).
We chose to use the highest concentrations of PCL-
([24.9 µg/mL]), PLLA- ([24.9 µg/mL]) and Au-NPs
([160.3 µg/mL]) for all experiments except cell viability to
make sure possible adverse effects would be detected.
Cell viability
The effect of PCL-, PLLA- and Au-NP exposure on the
viability of rBCEC4 cells was examined using the methylthia-
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Table 1: Antibodies.
antibody host company method dilution
primary
giantin rabbit Abcam IFc 1:250
LAMP1 rabbit Abcam IF 1:50
calreticulin rabbit Abcam IF 1:500
ATPB mouse Abcam IF 1:100
ZO-1/TJP1 mouse ThermoFisher IF/WBd 1:100/1:500
occludin rabbit Invitrogen IF/WB 1:100/1:500
Akt rabbit Cell Signaling WB 1:1000
phospho-Akt rabbit Cell Signaling WB 1:1000
pMAPK mouse Cell Signaling WB 1:1000–1:2000
phospho-pMAPK mouse Cell Signaling WB 1:1000–1:2000
NF-κB rabbit Cell Signaling WB 1:1000
phospho-NF-κB rabbit Cell Signaling WB 1:1000
β-catenin rabbit Cell Signaling WB 1:500
phospho-β-catenin rabbit Cell Signaling WB 1:500
claudin 3 rabbit Abcam WB 1:500
β-actin mouse Sigma Aldrich WB 1:10,000–1:20,000
secondary
anti-rabbit IgG AF 488a donkey Invitrogen IF 1:200–1:500
anti-mouse IgG AF 488 donkey Invitrogen IF 1:200–1:500
anti-rabbit IgG HRPb donkey Novex WB 1:5000–1:10,000
anti-mouse IgG HRP donkey Novex WB 1:5000–1:50,000
other
Hoechst — Life Technologies IF 1:10,000
Acti-Stain Phalloidin 488 — Cytoskeleton IF 1:50
aAF = Alexa Fluor, bHRP = horseradish peroxidase, cIF = immunofluorescence, dWB = western blotting.
zolyldiphenyl-tetrazolium bromide (MTT) (Sigma, Switzerland)
assay. Cells were seeded at 10,000 cells (96-well plate), left to
adhere and subsequently exposed to PCL-, PLLA- and Au-NPs
for 2 h or 24 h. Non-exposed cells were used as control. At the
end of NP exposure, exposed and non-exposed cells were incu-
bated with MTT dissolved in phosphate-buffered saline
(PBS) (Life Technologies, UK) for 4 h at 37 °C and 5% CO2
(final concentration: [0.5 mg/mL]). The cell culture medium
was removed and the remaining MTT-formazan was dissolved
in DMSO (Sigma, Switzerland). Absorbance was measured at
540 nm using a plate reader (Synergy HT, BioTek,
Switzerland).
Nanoparticle uptake
PCL-, PLLA- and Au-NP uptake was investigated using trans-
mission electron microscopy (TEM). PCL- and PLLA-NP
uptake was further examined by 3D-structured illumination
microscopy and quantified with high-content analysis. Briefly,
rBCEC4 cells were seeded at 36,000 cells (96-well plate) or
180,000 cells (24 well plate), left to adhere, then exposed to
either PCL-, PLLA- or Au-NPs for either 30 min, 2 h or 24 h at
37 °C and 5% CO2. Subsequently, the uptake of PCL- and
PLLA-NPs was assessed using a Zeiss Axio Imager Z1 plus
Apotome 1 (Carl Zeiss Vision Swiss AG, Feldbach, Switzer-
land) and evaluated quantitatively by high-content analysis with
the IN Cell Analyzer 2000 (GE Healthcare Life Sciences, USA)
[10,46].
Immunofluorescence staining
and transmission electron microscopy
After PCL- or PLLA-NP exposure, cells grown in 0.1% gelatin-
coated 96-well plates or on coverslips were fixed with cold
4% paraformaldehyde for 20 min at room temperature.
Following two washing steps with Dulbecco’s phosphate-
buffered saline (DPBS) (Life Technologies, UK), cells were
blocked with 10% horse serum in 0.4% Triton-PBS for 1–2 h at
room temperature. Subsequently, cells were incubated with pri-
mary antibodies overnight at 4 °C (Table 1). After washing four
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times with PBS, except for Acti-stain 488 phalloidin, the corre-
sponding secondary antibodies were applied and left for 2 h
before cells were washed again four times with PBS. There-
after, coverslips were mounted on glass slides using Glycergel
Mounting Medium (Dako, Denmark/USA). The samples were
examined and images were obtained using a Zeiss Axio Imager
Z1 coupled with an Apotome 1 (Carl Zeiss Vision Swiss AG,
Feldbach, Switzerland).
To further study uptake of PCL-, PLLA- and Au-NPs, rBCEC4
cells were seeded at 150,000 cells (24- well plate), coated with
0.1% gelatin and were incubated in cell culture medium at
37 °C and 5% CO2 until full confluence was reached. Cells
were then exposed to PLLA-NPs for 2 h, to PCL-NPs for 24 h
and Au-NPs for 2 and 24 h. Subsequently, TEM was performed
as previously described [11].
Western blotting or protein analysis
Cells were grown in T75-flasks, exposed to PCL-, PLLA- and
Au-NPs for 24 h and kept until they had grown to full conflu-
ence before extracting protein as described previously [9].
Equal amounts of protein from each sample were loaded and
separated on 10% to 16% SDS-PAGE gels and subsequently
transferred onto PVDF membranes. The membranes were
blocked for 2 h in blocking solution (5% milk in PBS and
0.2% Tween), then incubated with the respective primary anti-
body overnight at 4 °C on a shaker (Table 1). Following, the
membranes were washed four times, incubated with the corre-
sponding secondary antibody for 2 h at room temperature, and
washed again. Quantification was carried out with ImageJ by
measuring the intensity of the bands, given in arbitrary units,
and subsequent standardization on actin.
rBCEC4 monolayer permeability
rBCEC4 cells (90,000) were seeded per gelatin-coated Milli-
cell® culture plate insert with 3 µm pore size (Merck Millipore,
Germany) on days in vitro 0 (DIV0) and left to grow until
monolayer formation on DIV3. Except for control filters, cells
were exposed for 24 h to either PCL- or Au-NPs or stimulated
with 10% DMSO (positive control) on DIV2. Transendothelial
electrical resistance (TEER) was measured on DIV1 to DIV3
using the Millicell ERS-2 volt ohm meter (Merck Millipore,
Germany). TEER (Ω·cm2) of the cell monolayer was calculated
according to Equation 1 [47]:
(1)
RTotal is the resistance across the rBCEC4 cell layer on the
coated filter membrane, RBlank is the resistance across an empty
filter membrane (only coating, no cells) and AMembrane is the
surface area of the filter membrane.
The permeability assay on DIV3 using 4.4 kDa tetramethyl-
rhodamine isothiocyanate (TRITC) dextran and 70 kDa fluores-
cein isothiocyanate (FITC) dextran ([0.5 mg/mL]; Sigma,
Switzerland) was carried out as described previously [48].
Briefly, transport buffer (TB) was prepared with HEPES-
buffered Hank’s Balanced Salt Solution (HBSS) (Sigma,
Switzerland). Inserts were transferred to 24-well plates contain-
ing TB and filled with dextran solution. After 60 min the fluo-
rescence of samples from the donor and receiver solution at dif-
ferent time points was detected at 492 nm (excitation), 518 nm
(emission) and 550 nm, 580 nm for 70 kDa FITC-dextran and
4.4 kDa TRITC-dextran, respectively.
The apparent permeability coefficient (Papp; cm/s) was calcu-
lated according to Equation 2:
(2)
k is the transport rate defined as the slope obtained by using
linear regression on cumulative fraction absorbed (FAcum)
plotted versus time, VR is the volume in the receiver chamber
and A the surface area of the filter membrane. FAcum was
calculated from Equation 3:
(3)
CRi is the concentration in the receiver chamber at the end of
interval i and CDi the concentration in the donor chamber at the
beginning of interval i.
Statistical analysis
Statistical analysis was carried out with GraphPad Prism
(GraphPad Software Inc., La Jolla, USA). One-way ANOVA
was conducted, followed by Tukey’s multiple comparisons test
for all experiments performed. P-values ≤ 0.05 were consid-
ered statistically significant. All experiments were done in trip-
licates and repeated two to three times. Results are given as
mean, error bars indicate standard error of the mean (SEM).
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